ERNAW NASDAQ
Ernexa Therapeutics Inc. Warrants
1W: -8.9%
1M: -28.6%
3M: -51.5%
YTD: -68.1%
$0.03
-0.01 (-17.14%)
Weekly Expected Move ±43.6%
$0
$0
$0
$0
$0
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Supply Chain
Supply Chain Overview
36 relationships36
As Filer
counterparties named
0
As Counterparty
mentioned by others
6
Rel. Types
2021-03-31
Earliest Filing
2026-02-11
Latest Filing
partner: 20
target: 6
investor: 3
acquirer: 3
licensee: 2
supplier: 2
Counterparties (Filed by ERNAW)
36 relationshipsCompanies named in ERNAW's SEC 8-K filings as business counterparties.
| Counterparty | Ticker | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|---|
| Ernexa Therapeutics, Inc. | ERNAW | target | Company entering into a placement agency agreement for a securities offering | 2026-02-11 | View |
| Brookline Capital Markets | — | partner | Division of Arcadia Securities acting as placement agent | 2026-02-11 | View |
| Nasdaq Stock Market LLC | NDAQ | partner | Exchange entity responsible for listing the securities | 2026-02-11 | View |
| Factor Bioscience Limited | — | partner | Exclusive License and Collaboration Agreement for cancer, autoimmune, and rare disease technologies | 2024-09-27 | View |
| Factor Bioscience Limited | — | partner | Entered into an Exclusive Amended and Restated License Agreement with Eterna Therapeutics Inc. | 2023-11-16 | View |
| Factor Bioscience Limited | — | partner | Exclusive license agreement for Factor Patents including veterinary uses and maintenance fees | 2023-07-13 | View |
| Factor Bioscience Limited | — | partner | Licensor of intellectual property rights acquired by the Company | 2023-05-02 | View |
| Exacis Biotherapeutics Inc. | — | target | Seller of intellectual property assets in an asset purchase agreement | 2023-05-02 | View |
| Lincoln Park Capital Fund, LLC | — | investor | Committed to purchase up to $10.0 million of Eterna Therapeutics Inc.'s common stock and received 73,659 shares as a com | 2023-04-11 | View |
| Novellus Therapeutics Limited | — | partner | Party to prior Exclusive License Agreement | 2023-02-22 | View |
| Brooklyn Immunotherapeutics LLC | — | partner | Former name of Eterna Therapeutics LLC, party to prior agreement | 2023-02-22 | View |
| Eterna Therapeutics LLC | — | partner | Affiliate of Licensee, party to prior agreement | 2023-02-22 | View |
| Eterna Therapeutics Inc. | — | licensee | Licensee receiving exclusive license rights | 2023-02-22 | View |
| Factor Bioscience Limited | — | licensee | Licensor granting exclusive license rights | 2023-02-22 | View |
| Brooklyn Immunotherapeutics LLC | — | partner | Wholly owned subsidiary of Eterna Therapeutics Inc. that entered into the Amended Factor License Agreement. | 2022-11-22 | View |
| Novellus Therapeutics Limited | — | partner | Wholly owned subsidiary of Eterna Therapeutics Inc. that was removed from the Amended Factor License Agreement. | 2022-11-22 | View |
| Factor Bioscience Limited | — | partner | Licensor that granted an exclusive license to Brooklyn LLC and replaced Novellus in the agreement. | 2022-11-22 | View |
| E.R. Squibb & Sons, L.L.C. | — | partner | Sublessor for office and laboratory space sublease agreement | 2022-10-24 | View |
| Factor Bioscience Inc. | — | supplier | Agreed to provide mRNA cell engineering research support services under a Master Services Agreement. | 2022-09-15 | View |
| Factor Bioscience Limited | — | supplier | Subsidiary of Factor Bioscience Inc. that waived payment under a previously disclosed Exclusive License Agreement. | 2022-09-15 | View |
| Brooklyn ImmunoTherapeutics, Inc. | BTX | acquirer | Acquiring Novellus, Inc. in a merger and purchasing NoveCite, Inc. shares. | 2021-07-19 | View |
| Brooklyn Acquisition Sub, Inc. | — | acquirer | Special purpose acquisition vehicle used to acquire Novellus, Inc. | 2021-07-19 | View |
| Novellus LLC | — | target | Seller of NoveCite, Inc. shares and party to the merger. | 2021-07-19 | View |
| Novellus, Inc. | — | target | Target company in the merger and seller of NoveCite, Inc. shares. | 2021-07-19 | View |
| NoveCite, Inc. | — | target | Company whose shares are being acquired by Brooklyn ImmunoTherapeutics, Inc. | 2021-07-19 | View |
| Lincoln Park Capital Fund, LLC | — | investor | Entered into a purchase agreement and registration rights agreement to acquire up to $40.0 million of common stock. | 2021-05-26 | View |
| Novellus Therapeutics Limited | — | partner | Signed an exclusive license agreement to grant rights to develop and commercialize cell-based therapies. | 2021-04-30 | View |
| Factor Bioscience Limited | — | partner | Signed an exclusive license agreement to grant rights to develop and commercialize cell-based therapies. | 2021-04-30 | View |
| Lincoln Park Capital Fund, LLC | — | investor | Entered into a purchase agreement and registration rights agreement to acquire up to $20.0 million of common stock. | 2021-04-30 | View |
| Novellus Therapeutics Limited | — | partner | Licensor of intellectual property and mRNA cell reprogramming technology | 2021-04-15 | View |
| Factor Bioscience Limited | — | partner | Licensor of intellectual property and mRNA cell reprogramming technology | 2021-04-15 | View |
| BIT Merger Sub, Inc. | — | partner | Wholly owned subsidiary that merged with Brooklyn LLC | 2021-03-31 | View |
| eGames.com Holdings LLC | — | acquirer | Acquired assets relating to pre-Merger business | 2021-03-31 | View |
| Maxim Group LLC | MMS | partner | Financial adviser to Brooklyn LLC in connection with the Merger | 2021-03-31 | View |
| Brooklyn LLC | — | target | Target of the merger with Brooklyn ImmunoTherapeutics, Inc. | 2021-03-31 | View |
| Brooklyn ImmunoTherapeutics, Inc. | BTX | partner | Registrant filing 8-K regarding merger and asset sale | 2021-03-31 | View |
Recent 8-K Filings (20)
| Filing Date | Description | Type | SEC |
|---|---|---|---|
| 2026-09-16 | Regulation FD; Exhibits | View | |
| 2026-09-16 | Officer/Director Change | View | |
| 2026-07-02 | Shareholder Vote; Exhibits | View | |
| 2026-07-02 | Regulation FD; Exhibits | View | |
| 2026-06-26 | Officer/Director Change; Exhibits | View | |
| 2026-05-04 | Bylaws Amendment; Exhibits | View | |
| 2026-02-26 | Regulation FD Disclosure; Financial Statements and Exhibits | View | |
| 2026-02-11 | Entry into Material Definitive Agreement; Other Events; Financial Statements and Exhibits | Agreement | View |
| 2025-12-11 | Regulation FD Disclosure; Financial Statements and Exhibits | View | |
| 2025-07-07 | Changes in Registrant's Certifying Accountant; Financial Statements and Exhibits | View | |
| 2025-06-12 | Amendments to Articles of Incorporation or Bylaws; Financial Statements and Exhibits | View | |
| 2025-06-09 | Unregistered Sales of Equity Securities; Other Events | View | |
| 2025-06-02 | Amendments to Articles of Incorporation or Bylaws; Submission of Matters to a Vote of Security Holde | View | |
| 2025-04-03 | Entry into Material Definitive Agreement; Unregistered Sales of Equity Securities; Shareholder Nomin | Agreement | View |
| 2025-03-26 | Amendments to Articles of Incorporation or Bylaws; Financial Statements and Exhibits | View | |
| 2025-03-24 | Entry into Material Definitive Agreement; Creation of Direct Financial Obligation; Financial Stateme | Agreement | View |
| 2025-03-12 | Entry into Material Definitive Agreement; Creation of Direct Financial Obligation; Financial Stateme | Agreement | View |
| 2025-02-13 | Shareholder Nominations | View | |
| 2025-01-10 | Notice of Delisting or Transfer; Departure/Election of Directors; Appointment of Officers | View | |
| 2025-01-03 | Notice of Delisting or Transfer | View |
Data extracted from SEC EDGAR 8-K filings using NLP. Relationships are as disclosed in filing text.
Covers 2021–2026. View on SEC EDGAR